Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
39 trials
Recruiting nowPhase 3
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Recruiting nowPhase 3
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Running, not taking new patientsPhase 3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Recruiting nowPhase 3
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
Running, not taking new patientsPhase 3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Opening soonPhase 3
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Recruiting nowPhase 3
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Recruiting nowPhase 3
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Recruiting nowPhase 3
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
Recruiting nowPhase 3
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Recruiting nowPhase 3
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer
Recruiting nowPhase 3
Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
Recruiting nowPhase 3
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
Recruiting nowPhase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Recruiting nowPhase 3
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer